The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial anti...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:iScience
Huvudupphovsmän: Jasenosky, Luke D., Cadena, Cristhian, Mire, Chad E., Borisevich, Viktoriya, Haridas, Viraga, Ranjbar, Shahin, Nambu, Aya, Bavari, Sina, Soloveva, Veronica, Sadukhan, Supriya, Cassell, Gail H., Geisbert, Thomas W., Hur, Sun, Goldfeld, Anne E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Elsevier 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831822/
https://ncbi.nlm.nih.gov/pubmed/31402258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2019.07.003
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk